Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Accumulated Expenses (2019 - 2022)

Historic Other Accumulated Expenses for C4 Therapeutics (CCCC) over the last 4 years, with Q1 2022 value amounting to $309000.0.

  • C4 Therapeutics' Other Accumulated Expenses fell 6516.35% to $309000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $309000.0, marking a year-over-year decrease of 6516.35%. This contributed to the annual value of $413000.0 for FY2021, which is 1194.03% down from last year.
  • Latest data reveals that C4 Therapeutics reported Other Accumulated Expenses of $309000.0 as of Q1 2022, which was down 6516.35% from $413000.0 recorded in Q4 2021.
  • In the past 5 years, C4 Therapeutics' Other Accumulated Expenses ranged from a high of $887000.0 in Q1 2021 and a low of $164000.0 during Q3 2020
  • Its 4-year average for Other Accumulated Expenses is $370750.0, with a median of $294500.0 in 2019.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 6750.0% in 2020, then crashed by 6516.35% in 2022.
  • Over the past 4 years, C4 Therapeutics' Other Accumulated Expenses (Quarter) stood at $280000.0 in 2019, then skyrocketed by 67.5% to $469000.0 in 2020, then fell by 11.94% to $413000.0 in 2021, then decreased by 25.18% to $309000.0 in 2022.
  • Its last three reported values are $309000.0 in Q1 2022, $413000.0 for Q4 2021, and $201000.0 during Q3 2021.